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Abstract
Introduction: Diabetic macular edema (DME) is an important cause of vision loss. England has a national systematic
photographic retinal screening programme to identify patients with diabetic eye disease. Grading retinal photographs
according to this national protocol identifies surrogate markers for DME. We audited a care pathway using a spectral-
domain optical coherence tomography (SDOCT) clinic to identify macular pathology in this subset of patients.
Methods: A prospective audit was performed of patients referred from screening with mild to moderate non-proliferative
diabetic retinopathy (R1) and surrogate markers for diabetic macular edema (M1) attending an SDOCT clinic. The SDOCT
images were graded by an ophthalmologist as SDOCT positive, borderline or negative. SDOCT positive patients were referred
to the medical retina clinic. SDOCT negative and borderline patients were further reviewed in the SDOCT clinic in 6 months.
Results: From a registered screening population of 17 551 patients with diabetes mellitus, 311 patients met the inclusion
criteria between (March 2008 and September 2009). We analyzed images from 311 patients’ SDOCT clinic episodes. There
were 131 SDOCT negative and 12 borderline patients booked for revisit in the OCT clinic. Twenty-four were referred back to
photographic screening for a variety of reasons. A total of 144 were referred to ophthalmology with OCT evidence of
definite macular pathology requiring review by an ophthalmologist.
Discussion: This analysis shows that patients with diabetes, mild to moderate non-proliferative diabetic retinopathy (R1) and
evidence of diabetic maculopathy on non-stereoscopic retinal photographs (M1) have a 42.1% chance of having no macular
edema on SDOCT imaging as defined by standard OCT definitions of DME when graded by a retinal specialist. SDOCT imaging
is a useful adjunct to colour fundus photography in screening for referable diabetic maculopathy in our screening population.
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Introduction
The U.K. diabetic population is predicted to increase by 1.5
fold by 2030.[1] Since 75% of diabetics have diabetic retinopathy
20 years after diagnosis, there is an increasing burden on medical
retina clinics.[1,2] Diabetic retinopathy screening (DRS) services
have been established to reduce blindness due to sight threatening
retinopathy. Diabetic macular edema (DME) is a common cause
of sight-threatening retinopathy.[3] The Early Treatment Diabetic
Retinopathy Study (ETDRS) identified patients with diabetic
maculopathy at risk of vision loss. Macular laser was shown to
prevent vision loss if applied according to protocol when the level
of maculopathy reached so-called, ‘clinically significant macular
edema’ (CSME). CSME was identified by the examination of
stereoscopic fundus photographs, or a stereoscopic examination of
the fundus and was independent of visual acuity. Patients with less
severe levels of maculopathy, including so-called non-CSME levels
of edema, did not achieve benefit from laser.[4]
Stereoscopic screening photographs are expensive and the
inherent difficulty in diagnosing DME on retinal screening
photographs which are not stereoscopic led to the identification
of surrogate markers of DME, such as exudates and microaneu-
rysms or haemorrhage in association with vision loss.[5] This
results in referral of large numbers of patients, who do not have
DME or CSME, and underdiagnosis of patients with DME and no
retinal lesions or lesions with good visual acuity. Patients with a
variety of other retinal lesions (microaneurysms, small retinal
haemorrhages, exudates) and no evidence of macular edema or
CSME suffer needless anxiety and confusion, when referred from
community screening to hospital eye services.
There are multiple established international grading systems for
diabetic retinopathy and maculopathy.[6,7] The English National
Screening Committee (ENSC) has introduced a simplified
retinopathy grading system to facilitate population screening of
the retina on a large scale.[6,8] Patients graded as M1 are referred
to ophthalmology clinics to be seen within 13 weeks (see Table 1
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referrals from another photographic screening service in England
found that only 21% of patients graded as M1 by the screening
programme were judged by the ophthalmologist in clinic to
require laser treatment.[9]
Optical Coherence Tomography (OCT) is an established, well-
tolerated, non-invasive, non-contact method of imaging the
macula.[10–14] It is a more accurate and objective method of
diagnosing macular edema than clinical examination, even by
experts.[15–20] Furthermore, OCT imaging is an established
clinical trial endpoint for new treatments for DME. [21–24]
The spectral-domain OCT (SDOCT) machine used in this
audit allows technical staff to generate both a high quality fundus
photograph for retinal screening and a simultaneous OCT scan to
diagnose macular edema in under one minute per eye.[25] There
is the potential for longitudinal follow-up of individual patients
owing to the high level of repeatability, the potential to train
technical staff in grading principles and the opportunity for audit,
telemedicine, and automation.[5,18,26–30]
We have analyzed the OCT images from patients graded as
mild to moderate non-proliferative retinopathy with features on
non-stereoscopic retinal photography of maculopathy (ENSC
grade equivalent R1/M1) to find how many of these patients
had no evidence of macular edema.
Materials and Methods
A photographic diabetic retinal screening service (DRSS) based
in the endocrinology department at St George’s Hospital in South-
West London has been in operation since 1999. This service
participates in the English National Screening Programme and
adheres to the national protocols for image capture, technician
training, image grading, referral patterns and quality assurance.
The service has 17,551 patients with diabetes on its fully collated
list and uses the non-mydriatic fundus camera Topcon TRC-
NW6S with a Nikon D80 camera body attached to it to collect
fundus images after pupil dilation.[31] The protocol specifies 2
images per eye – one centred on the macula and the other on the
optic nerve – with a field size of 45 degrees. All images are graded
by trained staff according to National Screening Committee (NSC)
protocols. Referral of M1 disease is to the ophthalmology clinic
(Moorfields medical retina service) based on site.
We report a prospective audit of patients referred from DRSS
with R1/M1 maximal retinopathy in either eye attending an
SDOCT clinic. We selected this group on the basis that the only
reason for referral to an ophthalmologist would be the possible
presence of DME. Patients with proliferative diabetic retinopa-
thy, severe non-proliferative retinopathy or un-gradeable retinal
images in either eye were excluded from this analysis and were
referred in the usual way to ophthalmology clinics. We analyzed
all consecutive imaging episodes in an SDOCT clinic between
March 2008 and September 2009. Patients attending the
SDOCT clinic had a visual acuity measurement, colour fundus
photography and OCT scanning performed. A Topcon 3DOCT-
1000 SDOCT was used with a 512 A scans x 128 lines raster scan
protocol.[31] SDOCT scans were taken by trained technicians.
All images were graded by a single consultant ophthalmologist
specialising in medical retina as SDOCT positive (edema
present), borderline or negative. OCT features used to grade
scans as SDOCT positive were central subfield measurement
$250 microns (a standard clinical trial entry criteria for DME),
and additional criteria to include subjective features that may
indicate DME at a very early stage, as follows: the presence of
intra-retinal cysts, sub-retinal fluid and/or diffuse retinal edema
(retinal thickening with areas of reduced retinal reflectivity) on
more than one scan, or any of the above associated with a change
in the internal limiting membrane (ILM) contour, including
increased central macular thickness or loss of foveal contour.
These guidelines include and extend those used in clinical trials
[21–24,32]. SDOCT positive patients were referred to the
medical retina clinic according to the usual English national
protocols and timelines. SDOCT borderline scans had an intra-
retinal cystic space on a single scan without a change in the ILM
contour. SDOCT borderline and SDOCT negative patients were
booked for a further SDOCT clinic appointment in 6 months
and images were again graded. OCT scans were also used to
confirm the status of the original referral image as M1. For
example, some patients have a pale central lesion that could be
either exudate or a small drusen. This is easy to determine on an
OCT scan by the intra-retinal or sub-retinal position of the
hyper-reflective lesion. OCT negative scans without lesions
confirming the status as M1 were sent back for re-grading of
the original image (see Fig. 1 for clinical pathway for R1/M1
patients).
The main outcome measure was the number of SDOCT
positive, borderline and negative episodes. We also detected other
(non-diabetic) pathologies.
Retinopathy screening images were obtained according to UK
National Screening Committee guidelines and OCT images were
graded within the ophthalmology clinic. All analyses and data
transfer were performed without any associated patient specific
identifiers with the approval of the Local Ethics Committee and
Caldicott Guardian. As such written consent is not required for
patients’ information to be stored and used for research.
Table 1. ENSC grading.
ENSC Grade Clinical features
Retinopathy
Grade
R0 No diabetic retinopathy
R1 (Background) Microaneurysm(s), Retinal
haemorrhage(s) 6 any exudates (not within the
definition of maculopathy)
R2 (Pre-proliferative) venous beading venous loop
or reduplication intra-retinal microvascular
abnormality (IRMA) multiple deep, round or blot
haemorrhages Cotton Wool Spots (careful search
for above features)
R3 (Proliferative) new vessels on disc (NVD) new
vessels elsewhere (NVE) pre-retinal or vitreous
haemorrhage pre-retinal fibrosis 6 tractional
retinal detachment
Maculopathy
Grade
M0 No maculopathy
M1 M1 grade is defined as: Exudate within 1 disc
diameter (DD) of the centre of the fovea, or
circinate or group of exudates within the macula,
or retinal thickening within 1 DD of the centre of
the fovea (if stereo available), or any
microaneurysm or haemorrhage within 1 DD of
the centre of the fovea only if associated with a
best VA of (if no stereo) 6/12 or worse.
Photocoagulation P evidence of focal/grid laser to macula evidence
of peripheral scatter laser
Unclassifiable U Unobtainable/un-gradable
DD; disc diameter, VA; visual acuity.
doi:10.1371/journal.pone.0014811.t001
OCT Diabetic Macular Screening
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There were 311 patients with diabetes and a diagnosis of R1/
M1 on graded fundus images in either eye. These patients
underwent SDOCT imaging of the maculae of both eyes between
March 2008 and Sept 2009.The outcomes from the data collected
at SDOCT clinic visit (OCT scan, visual acuity and colour fundus
photography) are summarised in Table 2. The number of patients
who went through the patient pathway is included in Figure 1.Of
these, there were 7 patients with one or more un-assessable images
(technical failures, 2.3% of the total audit) that required referral to
an ophthalmology clinic. One hundred and nineteen screening
episodes (38.3% of the total) were SDOCT maculopathy positive
and referred to the medical retina clinic. One hundred and thirty
one SDOCT negative (42.1%) and 12 SDOCT borderline
episodes (3.9%) were given further appointments in the OCT
clinic. Twenty-four patients (7.7%) were referred back to screening
for a variety of reasons (Table 2). Twenty-five patients (8.0%) were
referred to ophthalmology for reasons other than technical failure
(Table 2).
Discussion
In developed countries, diabetic eye disease is the leading cause
of blindness in adults aged under 65 years.[33] Macular edema has
traditionally been assessed by a combination of clinical examina-
tion, stereoscopic retinal photographs and fluorescein angiogra-
phy, with considerable argument within the literature and within
the diabetic retinopathy screening community as to which method
represents the ‘gold standard’. In reality, all of these methods are
somewhat subjective and rely on an en face determination of
retinal thickening. OCT imaging creates a thickness profile of the
retina that mimics quite accurately the histological arrangement of
the retina and has the additional benefit of some measure of
objectivity.
The presence of clinically significant macular edema (CSME)
increases the risk of moderate visual loss to approximately 30% to
50%, depending on the level of baseline visual acuity. [34]
Diabetic macular edema (DME) was defined on the basis of
stereoscopic fundus photography in ETDRS studies.[4] This
technique is complicated and difficult to use in a clinical setting
and was replaced with contact fundus biomicroscopy, which was
found to be in close agreement with stereophotography,
particularly for CSME.[35] CSME was defined in the ETDRS
[4] as any retinal thickening within 500 microns of the center of
the macula, or hard exudates within 500 microns of the center of
the macula with adjacent retinal thickening, or retinal thickening
at least 1 disc area in size, any part of which is within 1 disc
diameter of the center of the macula. Noncontact fundus
biomicroscopy is more commonly used, but has been shown to
be slightly less sensitive than contact fundus biomicroscopy.[16]
There is no requirement for a particular visual acuity level to
diagnose CSME and therefore initiate treatment. This is a clinical
diagnosis used by an ophthalmologist in order to determine a level
of severity of edema that will require laser treatment in order to
prevent future vision loss. This is significantly different from the
definition of diabetic maculopathy used in photographic screening
programmes. For example, in the English National Screening
Programme (ENSP), if the only detectable abnormality within the
macula on the photograph is an isolated microaneurysm then it
only merits referral to an ophthalmologist when the visual acuity
falls to 20/40. There are arguments that the ENSP definitions will
not identify patients with macular edema and good visual acuity,
Figure 1. OCT clinic pathway. The number of patients identified in this study at each section of this pathway are highlighted. Note that any R2
and R3 identified at primary screening are referred directly to ophthalmology clinic and do not enter the SDOCT clinical pathway represented in
Figure 1.
doi:10.1371/journal.pone.0014811.g001
OCT Diabetic Macular Screening
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programmes for diabetic retinopathy. The solution to this problem
is to use stereoscopic fundus photography, which was considered
by the ENSP not to be sufficiently cost-effective or reliable outside
of the context of international grading centres and clinical trials.
A review of the literature regarding the reliability of a clinical
diagnosis of DME shows that this can be a quite variable
‘standard’. The sensitivity and specificity of a clinical diagnosis of
diabetic CSME on a dilated fundus examination with seven-field
stereo fundus photographs at a reading centre is 24% and 98%
respectively, with a positive predictive value 71%, and negative
predictive value 89%.[36] Harding et al. reported a sensitivity of
64% (20/33) for direct ophthalmoscopy by an experienced
ophthalmologist relative to biomicroscopy with 60- and 90-diopter
lenses by a retina specialist, for detection of sight-threatening
maculopathy, defined as hard exudates within 1 DD of fixation, a
circinate ring of hard exudates at least one disc area in size greater
than 1 DD from fixation or scars of focal/grid photocoagula-
tion.[37] Using a similar definition in approximately 700 eyes, Lee
et al. identified maculopathy about half as frequently with non-
stereo 45u photography as with biomicroscopy using a 90- diopter
lens (10.2% vs. 4.9%, kappa 0.44). [38] Another study reported
sensitivity of 45% for macular edema detected by retina specialists
using indirect ophthalmoscopy routinely and slit-lamp biomicros-
copy relative to seven-field stereoscopic photographs.[39] In the
ETDRS, for detection of CSME, examinations with slit-lamp
biomicroscopy by retina specialists who had developed the
definition of CSME had a sensitivity of 82% (533/650, kappa
0.61) relative to seven-field stereoscopic photographs.[35,40]
Another photographic method, fluorescein angiography, was
utilized in the ETDRS studies, but angiographic features were
not included in the diagnosis of CSME.
Spectral domain OCT demonstrates greater sensitivity than
fluorescein angiography in diagnosing cystoid macular edema
(CME). There were no cases of clinical diagnosis of CME that
were missed by SDOCT in a recent study. [20] A further recent
study systematically reviewed the performance of OCT as a
potential objective and quantitative alternative to fundus photog-
raphy as a gold standard. The expected operating point on the
summary ROC (Receiver operating characteristic), a pooled
estimate of all studies, corresponded to a sensitivity of 0.79 (95%
CI: 0.71–0.86), a specificity of 0.88 (95% CI: 0.80–0.93), a positive
likelihood ratio of 6.5 (95% CI: 4.0–10.7), and a negative
likelihood ratio of 0.24 (95% CI: 0.17–0.32). These values suggest
a good overall performance of OCT for diagnosing CSME.[10]
For these reasons, OCT measurement of DME is now utilized
as a standard clinical trial endpoint for treatments of DME in large
multi-centre trials.[21–24] In addition, there are now multiple
studies demonstrating high levels of repeatability of macular
thickness measurements made with OCT.[41-44] Although
caution should be exercised in that measurements cannot be used
interchangeably between OCT machines due to the underlying
software paradigm used to generate the retinal thickness.[45]. The
consistent and objective nature of OCT parameters has even lent
itself to evaluation as an automated tool for the assessment of
CSME. [46]
The role of OCT in systematic population screening of patients
with diabetes for DME has not been determined. There are
several large studies in process that may answer some of these
questions.[47] The principal questions to answer will be whether
OCT screening increases referral of patients with early disease
who are not at risk of vision loss, what is normal macular thickness
in patients with diabetes across a range of age groups, refractive
errors and ethnicities, what OCT parameters most closely match
Table 2. Outcome of primary SDOCT visits (n=311).
Outcome Reason No
Referred for maculopathy Positive OCT 119
Referred for other than maculopathy (n=25) Technical failure 7
Epiretinal membrane/traction 5
Age related macular degeneration 2
Branch retinal vein occlusion 1
Cataract 1
Macular telangiectasia 1
Central serous retinopathy 1
Refraction and primary care 1
Other: Hard drusen; choroidal folds, macular crystals; unexplained poor vision,
peripapillary lesion; RAP; pigment epithelial detachment
6
Further OCT (n=143) Negative OCT 131
Borderline OCT 12
Referred back to screening programme (n=24) Improved/unreliable VA 8
Resolved maculopathy 5
Drusen 6 RPE changes 4
Exudates .1 DD from fovea 4
Macula crystal 1
Other: refraction; artefact; 2
RAP; retinal angiomatous proliferation, RPE; retinal pigment epithelium, DD; disc diameter.
Table footnote: SDOCT borderline scans had an intra-retinal cystic space on a single scan without a change in the ILM contour. This group has recently been published
as having a variety of causes for this appearance, not limited to DME, and was identified as a group to be observed. [20]
doi:10.1371/journal.pone.0014811.t002
OCT Diabetic Macular Screening
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current costs of OCT can be reduced by advances in technology
and software, such as automation.
This audit does not aim to answer those questions, but to
evaluate the presence of macular pathology suggesting vascular
leakage on OCT imaging of patients with a photographic
screening diagnosis of M1. We aimed to refine the diagnosis of
M1 in favour of patients with maculopathy amenable to currently
available therapies i.e. those for DME, such as argon retinal laser,
intravitreal triamcinolone and intravitreal anti-VEGF therapies.
At present, the OCT parameters attributable to macular edema
are well defined – increased retinal thickness or intraretinal or
subretinal hyporeflective spaces representing extracellular fluid. In
our opinion, the OCT parameters that correlate with a clinical
diagnosis of CSME are insufficiently defined or validated to be
applied to a retinal screening programme. Our triage paradigm
was that all patients with evidence of definite edema should have a
clinical evaluation. It is possible that future studies may further
refine the OCT analysis and allow only the referral of patients
definitely requiring treatment.
There are interesting questions regarding whether neurodegen-
eration precedes the development of the vascular changes in
diabetic retinopathy. [48–50] Arguments regarding the effect of
retinal neurodegeneration caused by diabetes on retinal thickness
parameters are scientifically interesting, but, in the absence of
specific therapies aimed at this neurodegeneration, are of mostly
academic interest. More specifically, a patient with an equal
degree of retinal thinning due to neurodegeneration and retinal
thickening due to vascular leakage would have undetectable
changes on clinical examination or stereoscopic fundus imaging
and would not be considered to meet the thresholds for initiation
of therapy for macular edema.
This audit shows that, in an unselected screening population of
17, 551 patients with diabetes mellitus (type 1 and type 2) derived
from an urban inner city environment (central London, England)
311 were evaluated by standard photographic grading as having
mild to moderate non-proliferative diabetic retinopathy (R1) in
association with photographic surrogate markers of diabetic
maculopathy (M1). Of these, only 38.3% had OCT evidence of
macular edema and required examination by an ophthalmologist
to evaluate the need for treatment. We believe that OCT is a
useful adjunct to traditional photographic retinal screening and
warrants further evaluation, particularly with respect to the role of
OCT in screening pathways and the health economics of this
introduction.
This analysis shows that patients with diabetes, mild to
moderate non-proliferative diabetic retinopathy (R1) and evidence
of diabetic maculopathy on non-stereoscopic retinal photographs
(M1) have a 42.1% chance of having no macular edema on
SDOCT imaging as defined by standard OCT definitions of DME
when graded by a retinal specialist. SDOCT imaging is a useful
adjunct to colour fundus photography in screening for referable
diabetic maculopathy in our screening population.
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